Pharmacotherapy in Psychiatry and Neurology
eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Reviewers Instructions for authors
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

without publication fees

Open access

without publication fees
2/2025
vol. 41
 
Share:
Send email
Share:
Review article

Pharmacotherapy of acute migraine attacks – classic triptans and modern gepants

Wiktoria Biela
1
,
Kamila M. Czora-Poczwardowska
2
,
Weronika Jarczak
1
,
Aleksandra Tembłowska
1
,
Michał Szulc
2
,
Przemysław Mikołajczak
2
,
Radosław Kujawski
2

  1. Poznań University of Medical Sciences, Student Scientific Society, Student Pharmacology Science Club, Poznań, Poland; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Studenckie Towarzystwo Naukowe, Studenckie Koło Naukowe Farmakologii, Poznań, Polska
  2. Poznań University of Medical Sciences, Department of Pharmacology, Poznań, Poland; Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Katedra i Zakład Farmakologii, Poznań, Polska
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.159503
Online publish date: 2026/04/28
Article file
- Pharmacotherapy of acute migraine attacks – classic triptans and modern gepants.pdf  [0.53 MB]
Get citation
 
PlumX metrics:
 
1. Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61: 1021–39.
2. Borkum JM. CGRP and brain functioning: cautions for migraine treatment. Headache 2019; 59: 1339–57.
3. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 54–6.
4. Burch R. Migraine and Tension-Type Headache: Diagnosis and Treatment. Med Clin North Am 2019; 103: 215–33.
5. Cameron C, Kelly S, Hsieh S-C, Murphy M, Chen L, Kotb A, et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache 2015; 55 Suppl 4: 221–35.
6. Campos CA, Bowen AJ, Roman CW, Palmiter RD. Encoding of danger by parabrachial CGRP neurons. Nature 2018; 555: 617–22.
7. Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394: 1765–74.
8. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. Cochrane Database Syst Rev 2014; 2014: CD009108.
9. Domitrz I, Lipa A, Rożniecki J, Stępień A, Kozubski W. Migraine diagnosis and treatment in Poland: survey of primary care practitioners. Neurol Neurochir Pol 2021; 55: 380–386.
10. Edvinsson L. Rimegepant oral disintegrating tablet for migraine. Lancet 2019; 394: 711–2.
11. Eftekhari S, Salvatore CA, Gaspar RC, Roberts R, O’Malley S, Zeng Z, et al. Localization of CGRP receptor components, CGRP, and receptor binding sites in human and rhesus cerebellar cortex. Cerebellum 2013; 12: 937–49.
12. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633–58.
13. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459–80.
14. Ho TW, Ho AP, Ge YJ, Assaid C, Gottwald R, MacGregor EA, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia 2016; 36: 148–61.
15. Hong P, Tan T, Liu Y, Xiao J. Gepants for abortive treatment of migraine: A network meta-analysis. Brain Behav 2020; 10:e01701.
16. Hou M, Liu H, Li Y, Xu L, He Y, Lv Y, et al. Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics. Eur J Clin Pharmacol 2019; 75: 1369–78.
17. International Headache Society. The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia 2018; 38: 1–211.
18. Knyihár-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihály A, Vécsei L. Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000; 12: 3991–4002.
19. Law S, Derry S, Moore RA. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. Cochrane Database Syst Rev 2016; 4: CD008541.
20. Lipton RB, Munjal S, Buse DC, Alam A, Fanning KM, Reed ML, et al. Unmet acute treatment needs from the 2017 migraine in america symptoms and treatment study. Headache 2019; 59: 1310–23.
21. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014; 34: 114–25.
22. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986; 83: 5731–5.
23. Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs 2019; 28: 555–67.
24. Olesen J, Diener H-C, Husstedt IW, Goadsby PJ, Hall D, Meier U, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104–10.
25. Ornello R, Andreou AP, De Matteis E, Jürgens TP, Minen MT, Sacco S. Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine 2024; 99: 104943.
26. Puledda F, Sacco S, Diener H-C, Ashina M, Al-Khazali HM, Ashina S, et al. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine. Cephalalgia 2024; 44: 3331024241252666.
27. Puledda F, Younis S, Huessler E-M, Haghdoost F, Lisicki M, Goadsby PJ, et al. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature. Cephalalgia 2023; 43: 3331024231151419.
28. Sacco S, Lampl C, Amin FM, Braschinsky M, Deligianni C, Uludüz D, et al. European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 2022; 23: 133.
29. Schuster NM, Rapoport AM. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review. Clin Neuropharmacol 2017; 40: 169–74.
30. Soldin OP, Dahlin J, O’Mara DM. Triptans in pregnancy. Ther Drug Monit 2008; 30: 5–9.
31. Tfelt-Hansen P. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. Cephalalgia 2021; 41: 1499–505.
32. Thorlund K, Mills EJ, Wu P, Ramos E, Chatterjee A, Druyts E, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 2014; 34: 258–67.
33. Thorlund K, Toor K, Wu P, Chan K, Druyts E, Ramos E, et al. Comparative tolerability of treatments for acute migraine: A network meta-analysis. Cephalalgia 2017; 37: 965–78.
34. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985; 62: 131–6.
35. Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 2016; 36: 887–98.
36. Waqas M, Ansari FUR, Nazir A, Hussain KSR, Sarfraz Z, Sarfraz A, et al. Zavegepant nasal spray for the acute treatment of migraine: A meta analysis. Medicine (Baltimore) 2023; 102: e35632.
37. Xu H, Han W, Wang J, Li M. Network meta-analysis of migraine disorder treatment by NSAIDs and triptans. J Headache Pain 2016; 17: 113.
38. Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C, et al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Netw Open 2021; 4: e2128544.
39. Zhang Z, Shu Y, Diao Y, Du Y, Chen L, Liu Y, et al. Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis. Medicine (Baltimore) 2021; 100: e24741.
40. Zobdeh F, Ben Kraiem A, Attwood MM, Chubarev VN, Tarasov VV, Schiöth HB, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol 2021; 178: 4588–607.

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Termedia.